Comparative Pharmacology
Head-to-head clinical analysis: ASPARLAS versus TAZVERIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPARLAS versus TAZVERIK.
ASPARLAS vs TAZVERIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asparaginase (ASPARLAS) hydrolyzes L-asparagine to L-aspartic acid and ammonia, depleting circulating asparagine. Leukemic cells with low asparagine synthetase activity rely on exogenous asparagine; depletion inhibits protein and nucleic acid synthesis, leading to cell death.
TAZVERIK is a histone methyltransferase EZH2 inhibitor. It selectively inhibits the enzymatic activity of EZH2, leading to decreased trimethylation of lysine 27 on histone H3 (H3K27me3), which results in reactivation of silenced genes and inhibition of proliferation in EZH2-mutant or wild-type cells.
Intravenous (IV) or intramuscular (IM) injection: 2,500 IU/m² every 14 days as a component of multi-agent chemotherapy. Administer IV over 1-2 hours in 100 mL of 0.9% sodium chloride.
600 mg orally twice daily, with or without food, for advanced epithelioid sarcoma. Continue until disease progression or unacceptable toxicity.
None Documented
None Documented
The terminal elimination half-life is approximately 25.7 days (range 17.8–33.6 days) in children and 22.0 days in adults, allowing for dosing every 2 weeks instead of 3 times per week as with native E. coli asparaginase.
Terminal elimination half-life is approximately 3.6 hours (range 1.6–7.1 hours) in patients with epithelioid sarcoma at steady state. Short half-life supports twice-daily dosing. Consider accumulation with renal or hepatic impairment.
Calaspargase pegol (ASPARLAS) is eliminated via the reticuloendothelial system; renal excretion is negligible (<2% unchanged), and biliary/fecal excretion has not been quantified. The pegylated asparaginase is cleared through proteolytic degradation.
Primarily hepatobiliary excretion: approximately 70% of the dose recovered in feces as unchanged drug and metabolites, with <1% excreted renally as unchanged tazemetostat.
Category C
Category C
Antineoplastic, Enzyme
Antineoplastic, EZH2 Inhibitor